Stay updated with breaking news from Abx464. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Out of the 40 patients who enrolled into the ABX464 maintenance study, 23 patients have now reached the first year of treatment and all achieved at least an ACR20 [1] , with 19 and 12 patients achieving
End-of-phase-2 response from the US regulatory agency (FDA) provides guidance and a path forward to advance ABX464 into a phase 3 clinical program in ulcerative colitis (UC)PARIS, FRANCE / ACCESSWIRE /
Impressive clinical remission in 58.4% (ITT) of 101 patients after 48 weeks of once-daily oral 50mg ABX464, showing both maintained as well as further improved efficacyFavorable safety and tolerability
Guten Morgen mit Abivax SFC Energy Zur Rose Gruppe Epigenomics ... [pic1] Abivax erhält Genehmigung für Phase-1-Studie ABX464 an japanischen Probanden Emmi konstant positiver Entwicklung Rose-Gruppe beschleunigt Wachstum im zweiten Quartal Umsatzplus von 26% AG: Abschluss Biobank
Once-daily oral treatment was well-tolerated and demonstrated a good safety profile in Phase IIb study - News - PharmaTimes